JANX insider trading
HealthcareJanux Therapeutics, Inc.: insider trade history from SEC Form 4 filings.
About Janux Therapeutics, Inc.
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms technology to treat patients with cancer. Its clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer. Janux Therapeutics, Inc. has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. The company was incorporated in 2017 and is headquartered in San Diego, California.
Company website: www.januxrx.com
JANX insider activity at a glance
FilingIQ tracks 243 insider transactions for JANX in filings since Jun 16, 2021. The most recent transaction is dated Jul 31, 2026.
Across the full history, 19 open-market purchases
and 103 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on JANX insider trades is 56.0/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest JANX Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for JANX?
- FilingIQ tracks 243 Form 4 insider transactions for JANX (Janux Therapeutics, Inc.), covering filings from Jun 16, 2021 onwards. 1 of those are dated within the last 90 days.
- Are JANX insiders net buyers or net sellers?
- Across the full Form 4 history for JANX, 19 transactions (8%) were open-market purchases and 103 (42%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does JANX insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is JANX in?
- Janux Therapeutics, Inc. (JANX) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $791.24M.
Methodology & sources
Every JANX insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.